2-[[2-(Carboxymethylamino)-3-phenylpropanoyl]amino]-4-methylpentanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[[2-(Carboxymethylamino)-3-phenylpropanoyl]amino]-4-methylpentanoic acid
• 化学式: C₁₇H₂₄N₂O₅
• 分子量: 336.4
• InChiKey: JETREHBNPJNSMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  24
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  methyl 2-[[2-[(2-ethoxy-2-oxoethyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoate 生成 2-[[2-(Carboxymethylamino)-3-phenylpropanoyl]amino]-4-methylpentanoic acid
  参考文献：
  名称：

  ROQUES, B.;SCHWARTZ, J. -C.;LECOMTE, J. -M.

  摘要：

  DOI：

文献信息

• ROQUES, B.;SCHWARTZ, J. -C.;LECOMTE, J. -M.
  作者：ROQUES, B.、SCHWARTZ, J. -C.、LECOMTE, J. -M.

  DOI：——

  日期：——
• COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE
  申请人：Urigen Pharmaceuticals, Inc.

  公开号：EP3110427A1

  公开（公告）日：2017-01-04
• COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS
  申请人：PARSONS C. Lowell

  公开号：US20170189443A1

  公开（公告）日：2017-07-06

  The present invention is directed to a pharmaceutical composition comprising: (1) a therapeutically effective quantity of sodium pentosan polysulfate; (2) a quantity of a penetration enhancer sufficient to improve the bioavailability of the sodium pentosan polysulfate; and (3) optionally, a pharmaceutically acceptable carrier and to methods for the oral administration of sodium pentosan polysulfate with improved bioavailability for the treatment of interstitial cystitis and other urinary tract diseases and conditions. Such compositions and methods allow the administration of sodium pentosan polysulfate at lower dosages to reduce the frequency and severity of side effects.
• [EN] COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE<br/>[FR] COMPOSITIONS DE SELS DE POLYSULFATE DE PENTOSANE POUR ADMINISTRATION PAR VOIE ORALE ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：URIGEN PHARMACEUTICALS INC

  公开号：WO2015127416A1

  公开（公告）日：2015-08-27

  The present invention is directed to a pharmaceutical composition comprising: (1 ) a therapeutically effective quantity of sodium pentosan polysulfate; (2) a quantity of a penetration enhancer sufficient to improve the bioavailability of the sodium pentosan polysulfate; and (3) optionally, a pharmaceutically acceptable carrier and to methods for the oral administration of sodium pentosan polysulfate with improved bioavailability for the treatment of interstitial cystitis and other urinary tract diseases and conditions. Such compositions and methods allow the administration of sodium pentosan polysulfate at lower dosages to reduce the frequency and severity of side effects.